ASC35 / Ascletis - LARVOL DELTA

Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development (PRNewswire) - "ASC35 demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide in a head-to-head diet-induced obese (DIO) mouse study. Submission of an Investigational New Drug Application (IND) for ASC35 to the U.S. Food and Drug Administration (FDA) is expected in the second quarter of 2026."

IND • Preclinical • Obesity